Concepedia

Author

Stephanie Farnia

National Marrow Donor ProgramORCID

Also Known As

Stephanie Farnia, Stephanie H. Farnia

25

Publications

1K

Citations

13

H-Index

32

Concepts

All Affiliations

National Marrow Donor ProgramFred Hutch Cancer CenterMedical College of WisconsinThe University of Texas MD Anderson Cancer CenterMayo Clinic in Florida
SF

About

Stephanie Farnia is an author at National Marrow Donor Program specializing in medicine, hematology, and transplantation.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

79

2

Public Health

2

2

34

3

Cellular Therapies

2

2

45

4

Health Policy

2

2

34

5

Blood Transplantation

1

1

24

Stephanie Farnia

×

8

Publications

596

Citations

8

H-Index

YearCitations

Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation

Navneet S. Majhail, Stephanie Farnia, Paul A. Carpenter,

Biology of Blood and Marrow Transplantation

2015

403

Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome

Ehab Atallah, Brent R. Logan, Min Chen,

JAMA Oncology

2019

60

Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation

Jaime M. Preussler, Christa L. Meyer, Lih-Wen Mau,

Biology of Blood and Marrow Transplantation

2017

41

Standardization of Terminology for Episodes of Hematopoietic Stem Cell Patient Transplant Care

Charles F. LeMaistre, Stephanie Farnia, Stephen W. Crawford,

Biology of Blood and Marrow Transplantation

2013

24

Variation in Medicaid Coverage for Hematopoietic Cell Transplantation

Jaime M. Preussler, Stephanie Farnia, Ellen M. Denzen,

Journal of Oncology Practice

2014

24

Chimeric Antigen Receptor T-Cell Therapy

Ndiya Ogba, Nicole M. Arwood, Nancy L. Bartlett,

Journal of the National Comprehensive Cancer Network

2018

21

Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age

Ehab Atallah, Mary M. Horowitz, Brent R. Logan,

Blood

2015

13

Challenges around Access to and Cost of Life-Saving Medications after Allogeneic Hematopoietic Cell Transplantation for Medicare Patients

Stephanie Farnia, Alex Ganetsky, Alicia Silver,

Biology of Blood and Marrow Transplantation

2017

10

Page 1